TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

  • End date
    Oct 26, 2028
  • participants needed
  • sponsor
    City of Hope Medical Center
Updated on 4 October 2022
cell transplantation
acute chest syndrome
chest syndrome
Accepts healthy volunteers


This phase I trial tests the safety and effectiveness of total marrow and lymphoid irradiation (TMLI) and alemtuzumab as a conditioning regimen in patients with sickle cell disease. Conditioning regimens are treatments used to prepare a patient for stem cell transplantation. A stem cell transplant is a procedure in which a person receives blood stem cells, which make any type of blood cell. A conditioning regimen may include chemotherapy, monoclonal antibody therapy, and radiation to the entire body. It helps make room in the patient's bone marrow for new blood stem cells to grow, and helps prevent the patient's body from rejecting the transplanted cells. Alemtuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Graft-versus-host disease (GVHD) is a complication that may occur after hematopoietic cell transplantation (HCT) in which donated cells view the recipient's cells as foreign and attack them. Giving TMLI and alemtuzumab may help reduce organ damage that can be caused by radiation and decrease the risk of GVHD.



I. Evaluate the safety and feasibility of a fixed TMLI dose of 600 cGy with alemtuzumab as non-myeloablative conditioning (NMC) regimen in patients with sickle cell disease to achieve stable engraftment by Day +100 post HCT.


I. Assess the hematopoietic recovery by determining donor neutrophil engraftment, platelet engraftment.

II. Assess irradiation doses to non-target organs (lungs, heart, liver, spleen, kidneys, and gonads).

III. Assess the incidence of acute GvHD (grade II - IV) during the first 100 days after transplantation and chronic GvHD at 1 year post-HCT.

IV. Assess overall, event-free, and disease free survival at 1 year post-HCT. V. Assess donor chimerism at day +100 and 1 and 2 years after HCT.


I. Assess immune reconstitution post HCT on baseline, then on days +15, +30, +60, and +180, and 1-year post-HCT. II. Assessment of quality of life at baseline, Day+100, Day +180 and at 1-year post-HCT.

III. Define the impact of sickle cell disease (SCD) including inflammation on the bone marrow microenvironment and hematopoietic cells function at baseline.

IV. Monitor treatment response noninvasively on the recovery of bone marrow microenvironment (hematopoietic and vascular).

V. Monitor treatment response noninvasively on cerebral blood flow (CBF).


Patients receive alemtuzumab intravenously (IV) over 4 hours once daily (QD) on days -7 to -3. Patients undergo TMLI twice daily (BID) on day -2. Patients also undergo HCT on day 0 and receive sirolimus on day -1 and day 0.

After study treatment, patients are followed up on day 30, and for up to 2 years.

Condition Sickle Cell Disease
Treatment Sirolimus, alemtuzumab, Hematopoietic Cell Transplantation, intensity-modulated radiation therapy
Clinical Study IdentifierNCT05384756
SponsorCity of Hope Medical Center
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative
Assent, when appropriate, will be obtained per institutional guidelines
Registered into Risk Evaluation and Mitigation Strategies (REMS) program
Age: 2-40 years
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Have a diagnosis of sickle cell disease, be at a high risk for disease related morbidity or mortality, which must be defined by one of the following disease status
Significant neurologic event (stroke) or any neurological deficit lasting > 24 hours; or increased transcranial Doppler velocity (> 200 m/s)
History of one or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea)
History of one or more severe vaso-occlusive pain crises per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea)
Recurrent priapism requiring medical therapy
Osteonecrosis of two or more joints despite the institution of supportive care measures
Prior treatment with regular red blood cell (RBC) transfusion therapy, defined as receiving 8 or more transfusions per year for > 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
Echocardiograph finding of tricuspid valve regurgitation jet (TRJ) velocity >= 2.5 m/sec
Have a related donor who is matched on at least 8/10 human leukocyte antigen (HLA)-A
B, C, and DRB1 Loci
Total bilirubin =< 2.5 x upper limit normal (ULN( (unless has Gilbert's disease) (performed within 30 days prior to day 1 of protocol)
Aspartate aminotransferase (AST) =< 1.5 x ULN (performed within 30 days prior to day 1 of protocol)
Alanine aminotransferase (ALT) =< 1.5 x ULN (performed within 30 days prior to day 1 of protocol)
Creatinine clearance (CrCl) of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (performed within 30 days prior to day 1 of protocol)
If not receiving anticoagulants: International Normalized Ratio (INR) OR Prothrombin (PT) =< 1.5 x ULN (performed within 30 days prior to day 1 of protocol)
If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants
If not receiving anticoagulants: Activated Partial Thromboplastin Time (aPTT) =<1.5 x
ULN (performed within 30 days prior to day 1 of protocol)
If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants
Left ventricular ejection fraction (LVEF) >= 50% (performed within 30 days prior to
day 1 of protocol)
Note: To be performed within 28 days prior to Day 1 of protocol therapy
If able to perform pulmonary function tests: Forced expiratory volume in 1 second
(FEV1), force vital capacity (FVC), and diffused lung capacity of carbon
monoxide (DLCO) (diffusion capacity) >= 50% of predicted (corrected for
If unable to perform pulmonary function tests: Oxygen (O 2) saturation > 92% on room air
Note: To be performed within 28 days prior to Day 1 of protocol therapy
Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo
hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen
negative), and syphilis (rapid plasma regain [RPR])
If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed
Meets other institutional and federal requirements for infectious disease titer
Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test
If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be require
Agreement by females and males of childbearing potential to use an effective method of
birth control or abstain from heterosexual activity for the course of the
study through at least Six months after the last dose of protocol therapy
Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
DONOR: Age =< 60 years
DONOR: Medical history and physical examination confirm good health status as defined by institutional standards
DONOR: Serologies for: Hepatitis B (HBV) Core Antibody, HIV I/II Antibody, human T-lymphotropic virus (HTLV) - I/II antibody, HCV antibody, Hepatitis B surface antigen, Serologic Test for Syphilis, HIV-1/HCV/HBV nucleic acid, West Nile virus nucleic acid, Trypanosoma cruzi antibody, Cytomegalovirus (CMV) antibody, (AKA: Donor Room Serologies)
DONOR: Female donors of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (b-HCG) test within 30 days of initiation of conditioning, 30 days of patients admission for conditioning and 7 days of mobilization or bone marrow harvest
DONOR: The donor must be informed of the investigational nature of this study and have signed a consent form in accordance with Federal Guidelines and the guidelines of the participating institution

Exclusion Criteria

Prior allogeneic or autologous stem cell transplant
Patients who are receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
History of allergic reactions attributable to compounds of similar chemical or biologic composition to study agent
Patients with any active malignancy are ineligible for this study, other than non-melanoma skin cancers
Medical problem or neurologic/psychiatric dysfunction which would impair patient ability to be compliant with the medical regimen and to tolerate transplantation or would prolong hematologic recovery which in the opinion of the principal investigator would place the recipient at unacceptable risk
Active infection requiring antibiotics
Females only: Pregnant or breastfeeding
Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
DONOR: Evidence of active infection
DONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis if donating peripheral stem cells or unlikely to tolerate general anesthesia and bone marrow collection if donating a bone marrow
DONOR: Factors which place the donor at increased risk for complications from leukapheresis or granulocyte colony-stimulating Factor (G-CSF) therapy if donating peripheral stem cells or general anesthesia and bone marrow collection if donating a bone marrow
DONOR: Lactating female or, if of child-bearing potential, is unwilling to implement adequate birth control
DONOR: HIV positive
DONOR: Prior radiation therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note